Answers are grounded in this paper and cite their sources.
Hemoglobinopathies, which include the thalassemias and structural hemoglobin variants, are among the most common monogenic disorders worldwide, and southern China carries a particularly heavy burden. The molecular spectrum in Zhuzhou, a transitional zone between the high-prevalence provinces of Guangdong and Guangxi and the low-prevalence central region of Hunan Province, remains poorly characterized. Between January 2021 and December 2024, 27,834 individuals undergoing premarital or prenatal screening were examined by complete blood count and capillary hemoglobin electrophoresis; participants with abnormal findings underwent genetic analysis by gap-PCR, reverse dot-blot hybridization, and Sanger sequencing, and prenatal diagnosis was offered to at-risk couples. A total of 824 carriers were identified among the 5,288 participants referred for molecular analysis, yielding an overall detected carrier rate of 2.960% (95% CI 2.77%–3.17%), comprising 490 α-thalassemia (1.760%), 307 β-thalassemia (1.103%), 12 composite αβ-thalassemia (0.043%), and 15 abnormal hemoglobin variants (0.0539%). The α-globin spectrum was dominated by--SEA/αα (58.78%), and four β-globin alleles accounted for 89.90% of β-thalassemia alleles. Fifteen carriers of silent structural hemoglobin variants, representing three genotypes, with normal MCV and MCH values but abnormal electrophoretic fractions, were identified; Hb New York (HBB:c.341T>A, β113 Val > Glu) was the most frequent (73%). Thirty-one couples were confirmed to be carriers of the same trait, and prenatal diagnosis led to termination of seven pregnancies affected by severe phenotypes (three α-thalassemia homozygotes and four β-thalassemia compound heterozygotes). Zhuzhou is therefore a low-prevalence transitional zone with a molecular spectrum distinct from that of the high-prevalence south. Erythrocyte index-based screening alone would miss silent structural hemoglobin variants, and abnormal capillary electrophoresis findings should prompt molecular testing; prenatal diagnosis remains an effective strategy for preventing thalassemia-related birth defects.
No takes yet. Share an insight, caveat, or question.
Luo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: